<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336959</url>
  </required_header>
  <id_info>
    <org_study_id>CBCT197A2202</org_study_id>
    <secondary_id>2011-002735-25</secondary_id>
    <nct_id>NCT01336959</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of BCT197 in Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients
      undergoing cardiac surgery with cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function measured at 48 hours post cardiac surgery with cardiopulmonary bypass pump.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measurements of drug in patients undergoing cardiac surgery with cardiopulmonary bypass pump. Pharmacokinetics will be measured using AUC, Cmax, and Tmax.</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Open Label - BCT197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized double-blind BCT197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized double-blind BCT 197 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCT197 Part A</intervention_name>
    <arm_group_label>Open Label - BCT197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Randomized double-blind BCT 197 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCT197 Part B</intervention_name>
    <description>Randomized Double-blind BCT197</description>
    <arm_group_label>Randomized double-blind BCT197</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective cardiac surgery with CPB. Allowable procedures are
             CABG alone, aortic valve replacement or repair alone, mitral valve replacement or
             repair alone, CABG with aortic valve replacement or repair, and CABG with mitral valve
             replacement or repair. Patients with repeat surgery for any of the procedures can be
             included.

          -  Patients must weigh at least 50 kg to participate in the study, and must have a body
             mass index (BMI) 18 kg/m2

          -  Have an eGFR ≥ 30 and ≤ 60 mL/min/1.73 m2 to participate in Part A, or an eGFR &gt; 60
             mL/min/1.73 m2 to participate in Part B. Upon completion of Part A, patients with eGFR
             ≥ 30 mL/min/1.73 m2 may participate in Part B, with dose administered as per the
             dosing table

        Exclusion Criteria:

          -  left ventricular ejection fraction, in the last 6 months, ≥30%

          -  Active systemic infection or uncontrolled diabetes mellitus with a glucose ≥250 mg% at
             the screening assessment

          -  Pregnant or nursing (lactating) women,

          -  Female subjects must either:

        have been surgically sterilized or hysterectomized at least 6 months prior to study
        participation, or have had surgical bilateral oophorectomy (with or without hysterectomy)
        or tubal ligation at least six weeks prior to study participation. In the case of
        oophorectomy alone, only when the reproductive status of the woman has been confirmed by
        follow- up hormone level assessment is she considered not of child bearing potential,
        Surgical sterilization procedures or hysterectomy must be supported with clinical
        documentation made available to the sponsor and noted in the Relevant Medical History /
        Current Medical Conditions section of the CRF, OR be postmenopausal. Female subjects are
        considered post-menopausal and not of child bearing potential if they have had 12 months of
        natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age
        appropriate, history of vasomotor symptoms). Female subjects 60 years of age or younger
        must confirm menopause by the demonstration of a plasma FSH level in the postmenopausal
        range according to the lab normal range. Documentation of a prior plasma FSH level is
        acceptable

          -  History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of
             drug abuse as indicated by the laboratory assays conducted during screening or
             baseline

          -  New cancer diagnosis with planned chemotherapy and/or radiation therapy, or cancer
             requiring ongoing chemotherapy and/or radiation therapy at the time of screening

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herzelia</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>69710</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <disposition_first_submitted>May 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 20, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 15, 2015</disposition_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>CABG</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 25, 2017</submitted>
    <returned>November 27, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

